Friday, May 27, 2016

Fatty liver may increase the risk of heart disease

Patients suffering from fatty liver disease is prone to an increased risk of heart disease as well as the mortality rates associated with it, a new study has found.

Non-alcoholic fatty liver disease (NAFLD) is an increasingly common condition in patients with obesity, type 2 diabetes and arterial hypertension -- where high blood pressure in the arteries is persistently elevated.

The findings showed that NAFLD is an independent risk factor for atherosclerosis -- the build-up of fats, cholesterol and other substances in and on the artery walls -- which may lead to the advent of cardiovascular disease (CVD) -- heart diseases -- related deaths.

Evidence indicates that the fatty and inflamed liver expresses several pro-inflammatory and procoagulant factors, as well as genes involved in accelerated atherogenesis. This raises the possibility that the link between NAFLD and cardiovascular mortality might not simply be mediated by shared, underlying, common risk factors, but rather that NAFLD independently contributes to increasing this risk.

In patients with metabolic syndrome health problems like diabetes and stroke at risk for heart disease events, NAFLD contributes to early atherosclerosis and its progression, independent of traditional cardiovascular risk factors.

This indicates that NAFLD is a precursor of metabolic syndrome. It follows that the diagnosis of fatty liver is extremely important and therefore a thorough cardiovascular and metabolic work-up and strict monitoring of CVD or metabolic complications are needed in the clinical management of NAFLD.

Using the Fatty Liver Index (FLI) a well-validated biomarker, researchers observed that fatty liver is associated with thickness in the major blood vessels in the neck -- a pre-atherosclerotic problem that predicts heart disease events.

Thickness in the blood vessels increases proportionally with FLI, and this association is independent of traditional cardiometabolic risk factors -- like diabetes, heart disease or stroke.

Futher, patients with fatty liver were more likely to develop in the plaques resulting in thickness in the blood vessels over time. Fatty liver disease at baseline predicted the occurrence of carotid plaques independent of age, sex, type 2 diabetes, tobacco use, and other heart disease risk factors. Strict monitoring of cardiovascular disease is recommended when managing nonalcoholic fatty liver disease, the researchers suggested.

Sunday, May 22, 2016

Some Basic Understanding of Hepatitis B Blood Tests

Understanding your hepatitis B blood test results can be confusing.  It is important to discuss your test results with your health care provider so that you can clearly understand whether you have a new infection, chronic infection, or have recovered from an infection.

The information below is just to provide some basic understanding. Before explaining the tests, there are two basic medical terms that you should be familiar with:

Antigen:  A foreign substance in the body, such as the hepatitis B virus.

Antibody: A protein that your immune system makes in response to a foreign substance. Antibodies can be produced in response to a vaccine or to a natural infection. Antibodies usually protect you against future infections.

The test that is used to help you understand your hepatitis B status is called the hepatitis B blood panel. This is a simple 3-part blood test that your doctor can order.  Your results can be returned within 7-10 days.

The 3-part hepatitis B blood panel includes the following:
  1. Hepatitis B Surface Antigen (HBsAg): The “surface antigen” is part of the hepatitis B virus that is found in the blood of someone who is infected. If this test is positive, then the hepatitis B virus is present.
  2. Hepatitis B Surface Antibody (HBsAb or anti-HBs): The “surface antibody“ is formed in response to the hepatitis B virus. Your body can make this antibody if you have been vaccinated, or if you have recovered from a hepatitis B infection. If this test is positive, then your immune system has successfully developed a protective anti-body against the hepatitis B virus. This will provide long-term protection against future hepatitis B infection.  Someone who is surface antibody positive is not infected, and cannot pass the virus on to others.
  3. Hepatitis B Core Antibody (HBcAb or anti-HBc): This antibody does not provide any protection or immunity against the hepatitis B virus.  A positive test indicates that a person may have been exposed to the hepatitis B virus.  This test is often used by blood banks to screen blood donations.  However, all three test results are needed to make a diagnosis.
Use the following chart with help from your doctor to interpret your blood panel results:
What is hepatitis B?  Hepatitis B is the world’s most common serious liver infection. It is caused by the hepatitis B virus (HBV) that attacks liver cells and can lead to liver failure, cirrhosis (scarring) or cancer of the liver later in life. Approximately 90% of healthy adults who are exposed to the hepatitis B virus (HBV) recover on their own and develop the protective surface antibody. However, 10% of infected adults, 50% of infected children and 90% of infected babies are unable to get rid of the virus and develop chronic infection. These people need further evaluation by a liver specialist or doctor knowledgeable about hepatitis B.

Who should be tested? HBV is transmitted through contact with blood or infected bodily fluids,
through unprotected sex, unsterile needles, and from an infected mother to her newborn during the 
delivery process.  HBV is not transmitted  casually, through the air, or from casual social contact
(hugging, coughing, sneezing). 
The following groups are especially at high-risk for infection and should be tested:
  • Health care workers and emergency personnel
  • Partners or individuals living in close household contact with someone who is infected
  • Individuals who have had multiple sex partners or who have been diagnosed with an STD
  • Injection drug users
  • Men who have sex with men
  • Individuals who received a blood transfusion prior to 1992 
  • Individuals who have tattoos or body piercings 
  • Individuals who travel to countries where hepatitis B is common (Asia, Africa, South America, the Pacific Islands, Eastern Europe, and the Middle East)
  • Individuals emigrating from countries where hepatitis B is common, or who are born to parents who emigrated from these countries (see above)
  • ALL pregnant women should be tested for hepatitis B infection
Is there a vaccine for hepatitis B? There is a safe and effective vaccine for hepatitis B.  It is recommended in the U.S. and other countries for all infants and children up to age 18 and adults at high risk for infection.

Additional Diagnostic Tests:
Liver Function Tests (LFTs): These are a group of blood tests that help your doctor find out how well your liver is working.  The most important test is the following:
Alanine Aminotransferase (ALT): This is an enzyme that is released from liver cells into the bloodstream when the liver is injured.  An ALT  level above normal may indicate liver damage.  ALT levels are included in the regular monitoring of all chronic hepatitis B patients; this test can also be useful in deciding whether a patient would benefit from therapy, or for evaluating how well a current treatment is working.
Liver Biopsy: This involves the removal of a small piece of tissue from the liver using a special needle. The tissue is examined under a microscope to look for inflammation or liver damage.
Hepatitis B DNA test:  This is a highly sophisticated blood test that checks for the presence of hepatitis B virus DNA in the bloodstream.  The DNA test indicates how much virus is present in the blood.     
e-antigen: This is a protein that is made by the virus.  If this test is positive, it indicates that there is a lot of virus in the blood, which means that you can more easily spread the virus to others.  
e-antibody: Often as the virus stops replicating in the body, and the  e-antigen disappears from the blood, the e-antibody appears.  This can happen spontaneously or after treatment.